These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 28040692)

  • 21. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX).
    Kim JE; Hong YS; Kim HJ; Kim KP; Kim SY; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Kim JH; Kim TW
    Ann Surg Oncol; 2017 May; 24(5):1289-1294. PubMed ID: 27853901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance).
    Sinicrope FA; Mahoney MR; Yoon HH; Smyrk TC; Thibodeau SN; Goldberg RM; Nelson GD; Sargent DJ; Alberts SR;
    Clin Cancer Res; 2015 Dec; 21(23):5294-304. PubMed ID: 26187617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.
    Roth AD; Tejpar S; Delorenzi M; Yan P; Fiocca R; Klingbiel D; Dietrich D; Biesmans B; Bodoky G; Barone C; Aranda E; Nordlinger B; Cisar L; Labianca R; Cunningham D; Van Cutsem E; Bosman F
    J Clin Oncol; 2010 Jan; 28(3):466-74. PubMed ID: 20008640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
    André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
    J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
    Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.
    Ogino S; Shima K; Meyerhardt JA; McCleary NJ; Ng K; Hollis D; Saltz LB; Mayer RJ; Schaefer P; Whittom R; Hantel A; Benson AB; Spiegelman D; Goldberg RM; Bertagnolli MM; Fuchs CS
    Clin Cancer Res; 2012 Feb; 18(3):890-900. PubMed ID: 22147942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Associations between cigarette smoking status and colon cancer prognosis among participants in North Central Cancer Treatment Group Phase III Trial N0147.
    Phipps AI; Shi Q; Newcomb PA; Nelson GD; Sargent DJ; Alberts SR; Limburg PJ
    J Clin Oncol; 2013 Jun; 31(16):2016-23. PubMed ID: 23547084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
    Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
    Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA
    JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
    Gavin PG; Colangelo LH; Fumagalli D; Tanaka N; Remillard MY; Yothers G; Kim C; Taniyama Y; Kim SI; Choi HJ; Blackmon NL; Lipchik C; Petrelli NJ; O'Connell MJ; Wolmark N; Paik S; Pogue-Geile KL
    Clin Cancer Res; 2012 Dec; 18(23):6531-41. PubMed ID: 23045248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncologic outcomes after adjuvant chemotherapy using FOLFOX in MSI-H sporadic stage III colon cancer.
    Oh SY; Kim DY; Kim YB; Suh KW
    World J Surg; 2013 Oct; 37(10):2497-503. PubMed ID: 23754140
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic significance of BRAF mutation alone and in combination with microsatellite instability in stage III colon cancer.
    Chouhan H; Sammour T; L Thomas M; W Moore J
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):69-74. PubMed ID: 30421554
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Value of BRAF and KRAS Mutation in Relation to Colorectal Cancer Survival in Iranian Patients: Correlated to Microsatellite Instability.
    Nazemalhosseini-Mojarad E; Kishani Farahani R; Mehrizi M; Baghaei K; Yaghoob Taleghani M; Golmohammadi M; Peyravian N; Ashtari S; Pourhoseingholi MA; Asadzadeh Aghdaei H; Zali MR
    J Gastrointest Cancer; 2020 Mar; 51(1):53-62. PubMed ID: 30635874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.
    Fariña-Sarasqueta A; van Lijnschoten G; Moerland E; Creemers GJ; Lemmens VEPP; Rutten HJT; van den Brule AJC
    Ann Oncol; 2010 Dec; 21(12):2396-2402. PubMed ID: 20501503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of Molecular Status on Recurrence Site in Patients Treated for a Stage III Colon Cancer: a Post Hoc Analysis of the PETACC-8 Trial.
    Bruzzi M; Auclin E; Lo Dico R; Voron T; Karoui M; Espin E; Cianchi F; Weitz J; Buggenhout A; Malafosse R; Denimal F; Le Malicot K; Vernerey D; Douard R; Emile JF; Lepage C; Laurent-Puig P; Taieb J
    Ann Surg Oncol; 2019 Oct; 26(11):3561-3567. PubMed ID: 31209667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients.
    Yoon HH; Shi Q; Alberts SR; Goldberg RM; Thibodeau SN; Sargent DJ; Sinicrope FA;
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26160882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S; Kakuta M; Takahashi S; Takahashi A; Arai Y; Nishimura Y; Yatsuoka T; Ooki A; Yamaguchi K; Matsuo K; Muro K; Akagi K
    World J Gastroenterol; 2015 Jan; 21(4):1275-83. PubMed ID: 25632202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Association Between Mutations in BRAF and Colorectal Cancer-Specific Survival Depends on Microsatellite Status and Tumor Stage.
    Bläker H; Alwers E; Arnold A; Herpel E; Tagscherer KE; Roth W; Jansen L; Walter V; Kloor M; Chang-Claude J; Brenner H; Hoffmeister M
    Clin Gastroenterol Hepatol; 2019 Feb; 17(3):455-462.e6. PubMed ID: 29660527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.
    Roth AD; Delorenzi M; Tejpar S; Yan P; Klingbiel D; Fiocca R; d'Ario G; Cisar L; Labianca R; Cunningham D; Nordlinger B; Bosman F; Van Cutsem E
    J Natl Cancer Inst; 2012 Nov; 104(21):1635-46. PubMed ID: 23104212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.